T he lectin pathway of complement activation may play a complex role in cardiovascular disease (CVD). 1 Several large studies that investigated mannose-binding lectin (MBL) in relation to the risk of CVD have yielded contradictory findings. Studies that investigated MBL genotypes as proxies for circulating MBL consistently found that genotypes that result in low or deficient MBL were a risk factor for the development of CVD. [2] [3] [4] [5] This harmful effect of low MBL was explained by its role as a pattern-recognition molecule in the clearance of pathogens and apoptotic cells in the vessel wall. 6-8 However, when MBL concentrations instead of genotypes were investigated, several studies observed positive 9-11 rather than inverse 12 associations with future CVD. When the effect of MBL on complications of established CVD was investigated, low MBL was in fact protective in most studies. [13] [14] [15] Thus, considerable discrepancy remains in the literature on whether MBL has beneficial or adverse effects in CVD.
with low-grade inflammation, endothelial dysfunction, and carotid intima-media thickness (cIMT). A previous study on cIMT reported a U-shaped association of MBL concentrations with cIMT. 16 This study was, however, rather small (n=114) and was restricted to patients with rheumatoid arthritis. Besides, factors that mediate downstream complement activation through MBL have not yet been investigated in the development of CVD. MBL circulates in plasma as a complex with MBL-associated proteases (MASPs) and MBL-associated proteins (MAps) that mediate or regulate downstream complement activation. 7, 17, 18 In humans, MASPs and MAps have been measured in case-control studies or during acute cardiovascular events (CVEs), [19] [20] [21] but longitudinal studies on the role of MASPs and MAps in CVD are not yet available.
To gain more insight into the role of the lectin pathway in CVD, we investigated the recognition factor MBL, as well as factors that mediate downstream complement activation in a prospective human cohort study. We determined MBL concentrations and genotypes and, in addition, concentrations of MASP-1, MASP-2, MASP-3, and MAp44. We investigated their longitudinal associations with biomarker scores that reflect low-grade inflammation and endothelial dysfunction and with cIMT as a marker of subclinical vascular disease. [22] [23] [24] Furthermore, we determined their associations with incident CVD and incident CVEs over a 7-year follow-up period. Previous studies suggested that the effects of lectin-pathway activation in CVD could be both beneficial and adverse. Therefore, we investigated whether associations with cardiovascular outcomes were nonlinear. This provides a more comprehensive evaluation of the lectin pathway in the development of CVD.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Study Population
Five hundred seventy-four participants were included and extensively phenotyped. After a median follow-up of 7.0 years (interquartile range, 6.9-7.1 years), 495 individuals participated in follow-up measurements (for details, see flowchart, Figure I in the online-only Data Supplement). Table 1 shows the baseline characteristics of the complete study population. At baseline, 28% of the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) participants had CVD and 16% had CVE. In Table I characteristics across tertiles of MBL, MASP-1, MASP-2, MASP-3, and MAp44 and according to MBL genotypes, respectively, are provided. The MBL genotype frequencies were 62% A/A (=wild type), 33% A/0, and 5% 0/0. The A/A individuals were previously described to have highest MBL levels, whereas both the A/0 and 0/0 individuals have low MBL levels. 1, 4, 7, 10 For this reason, the A/0 and 0/0 individuals were combined into 1 group in the regression analyses. During the 7-year follow-up period, the 459 participants for whom we had complete follow-up data showed an increase in the inflammation score from −0.16±0.90 to 0.10±1.05, an increase in the endothelial dysfunction score from −0.12±0.94 to 0.08±1.04, and an increase in cIMT from 768±157 μm to 818±101 μm.
Of the 342 individuals who were free of CVD at baseline, 73 developed CVD (21%), of whom 39 experienced an event (CVE, 11%) during follow-up. Individuals with incident CVD had, at baseline, more often type 2 diabetes mellitus, more inflammation, more endothelial dysfunction, and a higher cIMT compared with those who remained free of CVD during follow-up period ( Table II in 
Associations of MBL With Low-Grade Inflammation and Endothelial Dysfunction
The association between plasma MBL and the low-grade inflammation score was nonlinear. During the 7-year followup period, the inflammation score was lowest in participants in the middle tertile (T Middle ) of MBL ( Table 2 ). In a regression model that was adjusted for age, sex, impaired glucose metabolism, and type 2 diabetes mellitus, the inflammation score was higher in the lowest (T Low ) tertile than in T Middle (0.18 SD [95% confidence interval, 0.01 to 0.36]) and was higher in the highest tertile (T High ) than in T Middle (0.18 SD [0.02 to 0.36]). After adjustment for potential confounders, the difference between T Low and T Middle remained significant (model 2, β=0.19 SD [0.03 to 0.34]), whereas the difference between T High and T Middle became borderline significant (β=0.15 SD [−0.02 to 0.31]). When participants with high C-reactive protein (CRP>10 mg/L, n=38 at baseline, n=42 at follow-up), indicative of acute inflammation, were excluded from the analyses, these associations were strengthened: the inflammation score was higher in T Low than in T Middle (0.25 SD [0.09 to 0.42]) and was higher in T High than in T Middle (0.19 SD [0.03 to 0.36]).
In contrast, plasma MBL was not associated with the endothelial dysfunction score (Table 2) , and these associations were not altered when participants with high CRP were excluded. There was no interaction between MBL and time in these generalized estimating equation models.
Associations of MBL With cIMT, Incident CVD, and Incident CVE
Deviations from linearity were also observed for the association between plasma MBL and cIMT. cIMT did not differ between T Low and T Middle . Participants in T High had the lowest cIMT ( Table 2 ). In the fully adjusted model, cIMT was not different between T Low and T Middle (β=−7 μm [−31 to 15]) and was lower in T High than in T Middle (β=−28 μm [−50 to −5]). The interaction term between T High and time was significant (P=0.044). Therefore, associations of MBL tertiles (measured only at baseline) with cIMT were analyzed separately for cIMT at baseline and at follow-up. In these stratified analyses, the difference in cIMT between T High and the 2 lower tertiles of MBL was more pronounced at baseline than at follow-up. In the fully adjusted model, baseline cIMT was 44 μm [−73 to −14] lower in T High than in T Middle of baseline MBL, whereas at follow-up, cIMT was only 7 μm [−29 to 14] lower in T High than in T Middle of baseline MBL. This implies a cross-sectional but no prospective association. When participants with high CRP were excluded from the analyses, the difference in cIMT between MBL T High and MBL T Middle was strengthened. This effect was observed in the unstratified generalized estimating equation association (β=−34 μm [−58 to −11]), as well as in the cross-sectional association (β=-52 μm [−83 to −22]).
The highest incidence of CVD and CVE was observed in MBL T Low , whereas T High had the lowest incidence of CVD and CVE (Table III in the online-only Data Supplement). For CVD, the difference between T High and T Middle was borderline significant in a model adjusted for age, sex, impaired glucose metabolism, and type 2 diabetes mellitus (model 1, OR=0.52 [0.26 to 1.02]). In the fully adjusted model, there were, however, no significant differences in CVD or CVE incidences between the tertiles. Associations with incident CVD and CVE were unchanged when participants with high CRP were excluded.
Table 2. Associations of Tertiles of Baseline Plasma MBL (ie, Recognition by the Lectin Pathway) With Inflammation, Endothelial Dysfunction, and cIMT During the 7-Year Follow-Up Period (GEE Analysis)
In addition to the actual MBL plasma concentrations, we investigated the genotypes that code for plasma MBL. Participants with genotypes coding for lower plasma MBL (ie, the A/0 and 0/0 individuals) had a slightly higher incidence of CVD (24% in A/0 and 0/0 combined versus 20% in A/A) and also of CVE (15% in A/0 and 0/0 combined versus 10% in A/A). These differences were not significant in the logistic regression analysis (model 2, combined A/0 and 0/0 compared with A/A, CVD, OR=1.20 [0.68 to 2.11]; CVE, OR=1.60 [0.73 to 3.51]).
Associations of MASP-1, MASP-2, MASP-3, and MAp44 With Low-Grade Inflammation and Endothelial Dysfunction
We did not observe deviations from linearity for associations of MASPs or MAp44 with the low-grade inflammation score or the endothelial dysfunction score; therefore, MASPs and MAp44 were analyzed as continuous variables.
MASP-1, MASP-2, MASP-3, and MAp44 were not associated with the inflammation score in the fully adjusted model (Table 3 ). There was no interaction between MASPs or MAp44 and time in these generalized estimating equation models.
MASP-1 and MASP-2 were not associated with the endothelial dysfunction score. In contrast, MASP-3 and MAp44 were positively associated with the endothelial dysfunction score ( Table 3 ). In the fully adjusted model (model 2), 1 SD higher baseline MASP-3 was associated with a higher endothelial dysfunction score (0.10 SD [0.02 to 0.18]). Regarding MAp44, 1 SD higher baseline MAp44 was associated with a higher endothelial dysfunction score (0.12 SD [0.04 to 0.20]). The interaction term with time was significant in the association between MASP-3 and the endothelial dysfunction score (P for interaction=0.049). Therefore, baseline and follow-up examinations were analyzed separately. In this stratified analysis, the positive association between MASP-3 (measured only at baseline) with the endothelial dysfunction score at baseline was slightly stronger than that with the endothelial dysfunction score at follow-up (baseline, β=0.12 SD [0.05 to 0.19]; follow-up, β=0.08 SD [−0.02 to 0.18]). These associations were not altered when participants with high CRP were excluded.
Associations of MASP-1, MASP-2, MASP-3, and MAp44 With cIMT, Incident CVD, and Incident CVE
We did not observe deviations from linearity in associations of MASPs or MAp44 with cIMT, incident CVD, or incident CVE. MASP-1, MASP-2, MASP-3, and MAp44 were not associated with cIMT in either model 1 or model 2 (Table 3 ). There was no interaction between MASP-1, MASP-2, or MASP-3 and time in any of these generalized estimating equation models. Because the interaction term with time was significant in the association between MAp44 and cIMT (P for interaction<0.001), baseline and follow-up examinations were analyzed separately. In this stratified analysis, however, no significant associations between baseline MAp44 and cIMT at either baseline or follow-up were observed (model ). There were no associations between MASP-1, MASP-2, MASP-3, or MAp44 with incident CVD or CVE (Table IV in the online-only Data Supplement). These associations were unchanged when participants with high CRP were excluded.
Sensitivity Analyses
To explore whether the respective associations of plasma MBL, MASP-3, and MAp44 with cardiovascular outcomes were independent of one another, we performed mutual adjustments. On additional adjustment for MASP-3 and MAp44, the association between MBL and the inflammation score was not materially altered: The inflammation score remained lower in T Middle of plasma MBL than T Low and T High (β for T Low =0.19 SD [0.03 to 0.34] and β for T High =0.13 SD [−0.03 to 0.30], respectively). Upon additional adjustment for MASP-3 and MAp44, cIMT remained lower in the highest tertile of plasma MBL (T High ) than in T Middle (β=−29 μm [−52 to −6]). Upon additional adjustment for MBL tertiles and MAp44, the association between MASP-3 and the endothelial dysfunction score remained significant (β was 0.08 SD [0.01 to 0.16]). Upon additional adjustment for MBL tertiles and MASP-3, the association of MAp44 with the endothelial dysfunction score remained significant (β was 0.10 SD [0.02 to 0.18]).
Discussion
The current study reports a comprehensive evaluation of the relation between proximal factors of the lectin pathway of complement activation and development of CVD. This study had several main findings: we observed a nonlinear association between MBL tertiles and low-grade inflammation, in which intermediate levels of baseline MBL were associated with the lowest levels of low-grade inflammation over the 7-year followup period. High plasma MBL was longitudinally associated with lower cIMT but was not significantly associated with CVD or endothelial dysfunction. Associations of MBL genotypes with CVD were also not significant. Higher concentrations of MASP-3 and MAp44 were associated with more endothelial dysfunction over the follow-up period, whereas this was not observed for MASP-1 or MASP-2. We did not observe an association of MASP-1, MASP-2, MASP-3, and MAp44 with lowgrade inflammation or cIMT nor with incident CVD or CVE.
These findings greatly extend existing knowledge. In previous studies, primarily unadjusted correlations between plasma MBL and a single inflammatory marker, such as CRP, were investigated. 4, 9, 11, 12, 25 Most of these studies found no correlation between MBL and inflammatory markers. Notably, these studies did not consider a potential nonlinear relationship. Our study is the first large, prospective study on MBL and cIMT. Previous studies on cIMT were cross-sectional, substantially smaller, and conducted in selected populations. 16, 26 We observed that high plasma MBL may protect against intimal-medial thickening, whereas the association of MBL with low-grade inflammation appeared to be nonlinear. This suggests that high MBL can have protective, as well as harmful, effects in the vasculature, which might explain why previous large studies on MBL and incident CVD have to some extent reported contradictory findings.
Our study is also the first large study that reports on the role of MASPs and MAp44 in the development of CVD. The few previous studies on MASPs in CVD were case-control studies, 19 or measured MASPs at admission for an acute CVE, 20 or measured only a single MASP (MASP-2). 21 During the 7-year follow-up period, the CODAM participants with plasma MBL levels in the lowest tertile were characterized by more inflammation than those in the middle tertile. This may be explained by impaired clearance of cellular waste because low MBL was shown to compromise the immune response and to limit the capacity to remove waste products such as apoptotic cells. 7, 8, 27 Consequently, individuals with low MBL may be more prone to develop low-grade inflammation as a result of chronic infections and impaired turnover of dysfunctional tissues. MBL was not associated with endothelial dysfunction, which suggests that associations of low MBL with higher low-grade inflammation and cIMT may indeed be explained by a crucial role of MBL in clear-up processes inside the vessel wall rather than by effects on endothelial activation or damage. Interestingly, the association between MBL and low-grade inflammation was not linear because high MBL also tended to be associated with more low-grade inflammation. Because MBL is a weak acute phase-reactant, 28, 29 we tested whether this finding might be driven by participants with elevated CRP concentrations indicative of acute inflammation. This was not the case, as upon exclusion of participants with elevated CRP, these associations were actually considerably strengthened: both low and high MBL concentrations were significantly associated with more low-grade inflammation, indicating a potentially U-shaped association. An association of high MBL with more low-grade inflammation may be explained by hyperresponsiveness to inflammatory triggers and initiation of autoinflammatory mechanisms by high MBL. 7, 27 This is supported by studies in ischemia-reperfusion injury, rheumatoid arthritis, or diabetic nephropathy, in which high MBL was associated with cardiovascular and renal damage. 10, 13, 14, 30, 31 We observed that participants with high plasma MBL had lower cIMT. This confirms a previously reported beneficial role of MBL in vascular integrity in a large study. 26 cIMT reflects pathological changes in the vessel wall that may result from early atherosclerosis and also from aging of the vessel wall. [22] [23] [24] High MBL may protect from intimalmedial thickening via its beneficial role in vascular clearup processes and tissue turnover. 7 Importantly, cIMT does not reflect the presence of atherosclerotic plaques. This may explain why the association in our study was weaker than the beneficial effect observed for high MBL genotypes on carotid plaque area. 32 Interestingly, the previously largest study on MBL and cIMT (n=114) reported a U-shaped association between MBL concentrations and cIMT, but that study included patients with rheumatoid arthritis and MBL concentrations were up to twice as high as in our study. 16 In line with our current findings, a smaller study in systemic lupus erythematosus patients who had MBL concentrations comparable with our study participants also reported that high plasma MBL was associated with lower cIMT. 26 In our study, participants with high plasma MBL appeared less likely to develop CVD and CVE. The same was observed for those with the wild-type genotype, but these latter associations were nonsignificant. High MBL thus seems to have beneficial effects in the vessel wall, despite higher systemic inflammation, which may be explained by the opsonic activity of MBL, potentially independent of downstream complement activation. 7, 8 Associations of MASP-1, MASP-2, MASP-3, and MAp44 with cardiovascular outcomes differed from those of MBL. During the 7-year follow-up period, MASP-3 and MAp44 were positively associated with endothelial dysfunction but not with low-grade inflammation. MASP-1 and MASP-2 were associated with neither low-grade inflammation nor endothelial dysfunction. Biological functions of MASP-3 and MAp44 are presently unresolved. In contrast to the proteases MASP-1 and MASP-2, for whom the enzymatic activities are well described, much less is known about MASP-3. MASP-3 may not be primarily involved in the activation of any downstream complement proteases 17, 18 but may rather be involved in developmental processes. 33, 34 MAp44 has no catalytic activity at all and is thought to exert biological functions only via binding to other proteins. 17, 18, 35 An effect of MAp44 is thus likely to involve a regulatory effect on activities of any of the 3 MASPs by, for instance, competing for binding to MBL. Notably, MBL, MASP-1, and MASP-2 were not associated with endothelial dysfunction, and associations of MASP-3 and MAp44 with endothelial dysfunction were independent of plasma MBL. This presents the possibility that these associations may be explained by effects beyond lectin-pathway activation. To date, the only identified substrate for MASP-3 is insulin-like growth factor-binding protein-5, 36 which regulates the activity of insulin-like growth factor. Insulin-like growth factor is increasingly implicated in endothelial function, 37 which might potentially explain our observations. Future research may clarify the functions of MASP-3 and MAp44 in lectinpathway regulation and potentially identify noncomplement substrates of MASP-3. Those insights are needed to understand how MASP-3 and MAp44 may contribute to endothelial dysfunction and indeed to basic tissue developmental processes. Other proteins, that is, ficolins and the collectin CL-LK, interact with MASPs and MAp44. 27 Whether the effect of MASP-3 and MAp44 is mediated via interactions with these other molecules also remains to be examined in future studies.
We did not observe associations of MASP-1, MASP-2, MASP-3, or MAp44 with cIMT, incident CVD, or CVE. This is in line with a previous case-control study on coronary artery disease. 19 Overall, plasma concentrations of MASPs and MAp44 do at this point of time not seem to confer any major contribution to cardiovascular risk.
The greatest strength of our study is the concomitant measurement of MBL, MASP-1, MASP-2, MASP-3, and MAp44 in a large, extensively phenotyped cohort. We acknowledge that this comprehensive evaluation of lectin-pathway factors involved multiple statistical tests, which may have increased the chance of false-positive findings. However, rigorous adjustment for multiple testing would increase the chance that a real biological association is not detected. In this study, we explored hypotheses generated from basic research to provide a first line of human evidence that could serve as a basis for further study. In the light of this aim, we argued that it would be undesirable to miss an association that does exist in the population. Therefore, and in agreement with current recommendations for observational studies, we did not formally adjust for multiple testing. 38 Another strength is that our study was large enough to investigate potential nonlinear associations with continuous outcomes. The primary limitation of our study is its observational nature. Moreover, the statistical power in the analysis of incident disease in our cohort was low. For incident CVE, the absolute number of events (n=39) may have been too small to draw robust conclusions. We still chose to present these data to provide a complete picture and to allow comparison of findings from our cohort to previously published findings on the lectin pathway and incident CVD and CVE. Lastly, our study cohort was selected for a moderately increased risk of cardiometabolic disease, which might limit the generalizability of our results. Notwithstanding, our cohort represents a large part of typical Western populations, namely middle-aged to elderly individuals who are overweight, modestly hypertensive, have some signs of disturbed glucose metabolism, or use medication for various reasons.
In conclusion, we showed that high plasma MBL was associated with lower cIMT, which can be explained by protective effects of MBL in vascular clear-up processes. In line with this, lower plasma MBL was associated with more low-grade inflammation. Notably, the association of plasma MBL with low-grade inflammation seemed to be nonlinear because high MBL also tended to be associated with more low-grade inflammation. The proteases MASP-1 and MASP-2, which induce downstream complement activation upon MBL-binding to ligands, were not associated with cardiovascular outcomes. This suggests that the capacity to recognize targets via MBL rather than the efficiency of MASP-1-and MASP-2-mediated complement activation is relevant to the role of the lectin pathway in inflammation and the vessel wall. MASP-3 and MAp44 were positively associated with endothelial dysfunction. Given that MBL itself was not associated with endothelial dysfunction, this suggests that MASP-3 and MAp44 potentially have functions in endothelial activation that are independent of lectin-pathway activation. These observations on factors of the lectin pathway are summarized in the graphical abstract. 
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